Markets concluded the week with a notable shift in sentiment. After reaching record highs earlier, U.S. stocks closed lower on Friday, impacted by macroeconomic concerns.

The Chicago Human Rhythm Project is celebrating 35 years of rhythm, culture and community with Rhythm World, a weeklong ...

Setmelanotide for the opportunity to treat acquired hypothalamic obesity on an Analyst/Industry conference call to be held on July 14 . Published first on TheFly – the ultimate source for real-time, ...

The next program of the Rhythm on the River Arts Series in Grand Rapids will be presented by Lake Effect Clarinet Quartet on ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

The Winthrop Rhythm & Blues Festival will bring musical talent from all over the globe — and from our own backyard — when it ...

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than ...

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Merck & Co. Inc. has strengthened its cardiopulmonary pipeline with its $10 billion acquisition of London-based-Verona Pharma plc. The deal brings Merck Ohtuvayre (ensifentrine) for chronic ...

Shares of US biopharma Rhythm Pharmaceuticals rose 27.4% to $82.96 in early trading today, as it announced positive top-line ...